Tatva Chintan Pharma Chem Ltd
TATVATatva Chintan Pharma Chem Ltd
TATVA
Price Chart
Scorecard
Performance
LowHasn't fared well - amongst the low performers
Valuation
HighSeems to be overvalued vs the market average
Growth
LowLagging behind the market in financials growth
Profitability
HighShowing good signs of profitability & efficiency
Entry point
AvgThe stock is overpriced but is not in the overbought zone
Red flags
LowNo red flag found
How to use scorecard? Learn more
Key Metrics
| No LabelNo Label | PB RatioPB Ratio | Dividend YieldDiv. Yield |
|---|---|---|
| 120.14 | 2.87 | 0.22% |
| Sector PESector PE | Sector PBSector PB | Sector Div YldSctr Div Yld |
|---|---|---|
| 30.76 | 3.47 | 1.33% |
Forecast & Ratings
Detailed Forecast from 3 analysts
Price
Price Upside
Earnings
Earnings Growth
Revenue
Rev. Growth
Company Profile
Tatva Chintan Pharma Chem is engaged in the manufacturing business of chemical products.
Investor Presentation
View olderPeers
Compare with peersGujarat Fluorochemicals Ltd
Vinati Organics Ltd
Akzo Nobel India Ltd
Navin Fluorine International Ltd
Aarti Industries Ltd
Get more out of Tickertape, Go Pro!
Customise key metrics, see detailed forecasts, download stock data and more
Forecasts
Price
Revenue
Earnings
Price Forecast
All values in ₹
All values in ₹
Revenue Forecast
All values in ₹ cr.
All values in ₹ cr.
Earnings Per Share Forecast
All values in ₹
All values in ₹
Income
Balance Sheet
Cash Flow
Income Statement
| Financial Year | FY 2018 | FY 2019 | FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | TTM | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | 137.29 | 207.55 | 264.62 | 305.56 | 442.54 | 429.35 | 401.01 | 378.72 | ||||||||
Raw Materials | 74.16 | 118.57 | 148.61 | 156.06 | 258.17 | 220.39 | 182.36 | 326.62 | ||||||||
| Power & Fuel Cost | 4.65 | 6.25 | 8.96 | 9.92 | 22.62 | 23.61 | 34.78 | |||||||||
| Employee Cost | 12.27 | 16.31 | 20.53 | 23.80 | 30.81 | 41.21 | 54.76 | |||||||||
| Selling & Administrative Expenses | 16.15 | 25.04 | 27.15 | 30.70 | 51.99 | 44.94 | 39.13 | |||||||||
| Operating & Other expenses | 5.45 | 6.02 | 2.72 | 13.20 | -38.46 | 36.27 | 14.08 | |||||||||
EBITDA | 24.61 | 35.36 | 56.65 | 71.88 | 117.41 | 62.93 | 75.90 | 52.10 | ||||||||
| Depreciation/Amortization | 2.95 | 4.02 | 4.79 | 6.73 | 8.18 | 9.56 | 25.61 | 26.29 | ||||||||
| PBIT | 21.66 | 31.34 | 51.86 | 65.15 | 109.23 | 53.37 | 50.29 | 25.81 | ||||||||
| Interest & Other Items | 2.63 | 3.95 | 4.27 | 4.45 | 5.11 | 8.60 | 6.73 | 1.07 | ||||||||
| PBT | 19.03 | 27.39 | 47.59 | 60.70 | 104.12 | 44.77 | 43.56 | 24.74 | ||||||||
| Taxes & Other Items | 6.75 | 6.85 | 9.81 | 8.43 | 8.25 | -0.70 | 13.22 | 7.11 | ||||||||
| Net Income | 12.28 | 20.54 | 37.78 | 52.27 | 95.87 | 45.47 | 30.34 | 17.63 | ||||||||
| EPS | 6.11 | 10.23 | 18.81 | 26.02 | 45.38 | 20.51 | 13.32 | 7.54 | ||||||||
| DPS | 0.00 | 0.00 | 0.00 | 5.00 | 2.00 | 2.00 | 2.00 | 2.00 | ||||||||
| Payout ratio | 0.00 | 0.00 | 0.00 | 0.19 | 0.04 | 0.10 | 0.15 | 0.27 |
Company Updates
Peers & Comparison
MaterialsSpecialty Chemicals
Valuation
Technical
Forecast
Compare valuation on Screener| Stock | PE RatioPE Ratio | PB RatioPB Ratio | Div. YieldDividend Yield |
|---|---|---|---|
| Tatva Chintan Pharma Chem Ltd | 69.81 | 2.87 | 0.22% |
| Gujarat Fluorochemicals Ltd | 105.21 | 7.71 | 0.07% |
| Vinati Organics Ltd | 61.39 | 8.06 | 0.37% |
| Akzo Nobel India Ltd | 43.68 | 14.01 | 1.59% |
Price Comparison
Compare TATVA with any stock or ETFShareholdings
Promoter Holdings Trend
Total Promoter Holding
In last 6 months, promoter holding in the company has almost stayed constant
Low Pledged Promoter Holding
Pledged promoter holdings is insignificant
Institutional Holdings Trend
Increased Total Retail Holding
In last 3 months, retail holding in the company has increased by 3.52%
Foreign Institutional Holding
In last 3 months, foreign institutional holding of the company has almost stayed constant
Shareholding Pattern
Dec 2023
Mar 2024
Jun 2024
Sep 2024
Shareholding History
Mutual Funds Holding Trend
Decreased Mutual Fund Holding
In last 3 months, mutual fund holding of the company has decreased by 3.84%
Top 5 Mutual Funds holding Tatva Chintan Pharma Chem Ltd
| Funds (Top 5) | The rupee value of the stock held by the fund divided by the stock’s market cap Market-cap held | Percentage of the fund’s portfolio invested in the stock Weight | Change in the portfolio weight of the stock over the last 3 months 3M holding change | The rank of the stock in the fund’s portfolio based on its weight in the portfolio along with the change in the rank over the last 3 months Portfolio rank(3M change) |
|---|---|---|---|---|
Nippon India ELSS Tax Saver Fund - Growth - Direct Plan Growth | The rupee value of the stock held by the fund divided by the stock’s market cap 3.7622% | Percentage of the fund’s portfolio invested in the stock 0.49% | Change in the portfolio weight of the stock over the last 3 months -0.05% | The rank of the stock in the fund’s portfolio based on its weight in the portfolio along with the change in the rank over the last 3 months 59/65 (0) |
ICICI Prudential Smallcap Fund - Growth - Direct Plan Growth | The rupee value of the stock held by the fund divided by the stock’s market cap 1.3027% | Percentage of the fund’s portfolio invested in the stock 0.30% | Change in the portfolio weight of the stock over the last 3 months -0.06% | The rank of the stock in the fund’s portfolio based on its weight in the portfolio along with the change in the rank over the last 3 months 48/117 (0) |
Nippon India Small Cap Fund - Growth - Direct Plan Growth | The rupee value of the stock held by the fund divided by the stock’s market cap 1.1893% | Percentage of the fund’s portfolio invested in the stock 0.04% | Change in the portfolio weight of the stock over the last 3 months -0.08% | The rank of the stock in the fund’s portfolio based on its weight in the portfolio along with the change in the rank over the last 3 months 169/238 (-5) |
Compare 3-month MF holding change on Screener
Hmm, looks like there hasn't been any net deal activity in the last 6 monthssmallcases
Looks like this stock is not in any smallcase yet.
Events
Dividend Trend
No dividend trend available
Dividends
Corp. Actions
Announcements
Legal Orders
Upcoming Dividends
No upcoming dividends are available
Past Dividends
Cash Dividend
Ex DateEx DateSep 6, 2024
Dividend/Share
₹2.00
Ex DateEx Date
Sep 6, 2024
Cash Dividend
Ex DateEx DateSep 8, 2023
Dividend/Share
₹2.00
Ex DateEx Date
Sep 8, 2023
Cash Dividend
Ex DateEx DateSep 8, 2022
Dividend/Share
₹2.00
Ex DateEx Date
Sep 8, 2022
Net loss of Tatva Chintan Pharma Chem reported to Rs 0.66 crore in the quarter ended September 2024 as against net profit of Rs 7.78 crore during the previous quarter ended September 2023. Sales declined 13.63% to Rs 83.49 crore in the quarter ended September 2024 as against Rs 96.67 crore during the previous quarter ended September 2023. ParticularsQuarter EndedSep. 2024Sep. 2023% Var. Sales83.4996.67 -14 OPM %6.6820.94 - PBDT5.7917.99 -68 PBT-1.0211.21 PL NP-0.667.78 PL Powered by Capital Market - Live
Tatva Chintan Pharma Chem will hold a meeting of the Board of Directors of the Company on 25 October 2024.Powered by Capital Market - Live
Tatva Chintan Pharma Chem announced that the Annual General Meeting (AGM) of the company will be held on 20 September 2024.Powered by Capital Market - Live
Purple Finance Ltd leads losers in ‘B’ group
Tatva Chintan Pharma Chem consolidated net profit declines 45.16% in the June 2024 quarter
Net profit of Tatva Chintan Pharma Chem declined 45.16% to Rs 5.21 crore in the quarter ended June 2024 as against Rs 9.50 crore during the previous quarter ended June 2023. Sales declined 7.78% to Rs 105.46 crore in the quarter ended June 2024 as against Rs 114.36 crore during the previous quarter ended June 2023. ParticularsQuarter EndedJun. 2024Jun. 2023% Var. Sales105.46114.36 -8 OPM %11.9718.66 - PBDT13.4719.43 -31 PBT6.8113.42 -49 NP5.219.50 -45 Powered by Capital Market - Live
Tatva Chintan Pharma Chem will hold a meeting of the Board of Directors of the Company on 24 July 2024.Powered by Capital Market - Live
Tatva Chintan Q4 Results Review - Revenue May Rise 25% With Expansion In Margin: ICICI Securities
Tatva Chintan - Delay In EU 7 Implementation Poses Risk To SDA Growth: Nirmal Bang
Accumulate Tatva Chintan Pharma Chem; target of Rs 1487: KR Choksey
Higher than Industry Revenue Growth
Over the last 5 years, revenue has grown at a yearly rate of 14.08%, vs industry avg of 6.09%
Increasing Market Share
Over the last 5 years, market share increased from 0.37% to 0.48%
Higher than Industry Net Income
Over the last 5 years, net income has grown at a yearly rate of 8.11%, vs industry avg of -1.55%